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Background. Extrapulmonary tuberculosis (EPTB) represents an increasing percentage of tuberculosis (TB) cases in Europe. 
However, strategies on TB prevention and successful treatment outcomes primarily target pulmonary TB. In this nationwide study, 
we present characteristics of EPTB, treatment outcomes, and predictors for unfavorable treatment outcomes.
Methods. All patients diagnosed with EPTB from 2009 to 2014 were included. Logistic regression analyses were used to identify 
risk factors for unfavorable outcome. The following definitions were used: unfavorable outcome: the sum of treatment failed, lost to 
follow-up, and not evaluated; patient delay: time from TB-related symptom onset until first hospital contact related to TB; doctor 
delay: time from first TB-related contact in the health care system to start of TB treatment.
Results. A total of 450 EPTB cases were notified, which represented 21.1% of all TB cases in Denmark. Immigrants accounted 
for 82.9%. Lymph nodes were the most common site of EPTB (55.4%) followed by pleural TB (13.4%). Patient delay was significantly 
longer among immigrants than Danes (60 vs 30 days; P < .01), whereas doctor delay was significantly longer among Danes (38.5 vs 
28 days; P < .01). Treatment completion rates were high and reached 90.9% in 2014. Male gender (odds ratio [OR], 5.18; 95% confi-
dence interval [CI], 1.79–15.04) and age 0–24 years (OR, 16.39; 95% CI, 2.02–132.64) were significantly associated with unfavorable 
outcome.
Conclusions. EPTB represented a significant number of all TB cases and was predominantly seen among younger immigrants in 
Denmark. To maintain high treatment completion rates, increased focus on male gender and young age is needed.
Keywords. epidemiology; extrapulmonary tuberculosis; low incidence; surveillance; treatment outcome.
Extrapulmonary tuberculosis (EPTB) represents 20% of tuber-
culosis (TB) cases in the majority of countries in the European 
Union (EU) [1, 2], and even in resource-rich settings, the man-
agement of EPTB remains a challenge due to difficulties in 
diagnosis, delay in treatment and monitoring of treatment out-
comes [3]. This is due to the varying localization, appearance, 
and pausibacillary nature and requirement of invasive sam-
pling. Patients with extrapulmonary localization to the central 
nervous system, bone, or abdomen have a higher risk of sequela 
after completion of treatment, which may interfere with assess-
ment of the outcome [4–8].
Overall, in the EU and the European Economic Area (EEA), 
TB notification rates have been decreasing since 2002 due to 
decreasing rates of pulmonary TB. Conversely, the rates for 
EPTB have remained stable, and consequently the proportion 
of EPTB has been increasing from 16.4% in 2002 to 22.8% in 
2016 in the EU/EEA [1, 2]. Similar results have been reported 
in the United States [9].
Pulmonary TB, which is the main source of Mycobacterium 
tuberculosis (Mtb) transmission, still accounts for the majority 
of TB cases. However, EPTB contributes considerably to mor-
bidity, lifelong sequelae, and mortality [4–8]. Routine contact 
tracing is generally only recommended in patients with smear-
positive pulmonary TB [10, 11]. Yet, a recent study from the 
United Kingdom performed in a high–TB incidence setting 
found that EPTB cases were an indicator of household active 
and latent TB [12].
EPTB does not receive the same attention as pulmonary TB, 
and treatment outcomes for EPTB are often not referred to in 
TB control programs. Studies on treatment outcome in EPTB in 
low-incidence countries are scarce, and the treatment comple-
tion rates are reported with great discrepancies: from 56.9% to 
89.2% [1, 8, 13–15]. The most recent Danish study from 1992 
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reported a treatment completion rate for culture-positive EPTB 
of 67.6% [14]. Because reporting of TB treatment outcome is 
voluntary in Denmark, reports are often incomplete, and ac-
curate information regarding treatment outcome in EPTB is 
missing. As a result, there is a need to address EPTB specifically, 
as this disease manifestation represents a significant burden of 
morbidity and mortality and has an impact on the health care 
system.
This study was conducted to elucidate EPTB treatment com-
pletion rates and to explore predictors for unfavorable treat-
ment outcome in Denmark from 2009 to 2014.
METHODS
We conducted a nationwide retrospective cohort study in 
Denmark from January 1, 2009, to December 31, 2014.
Study Population
As part of a larger study, all TB cases notified were identified. 
All patients notified with EPTB were included in this study, 
whereas outcomes for patients with pulmonary TB are reported 
elsewhere. EPTB was defined according to the European Centre 
for Disease Prevention and Control (ECDC) classification: any 
bacteriologically confirmed or clinically diagnosed case of TB 
involving organs or anatomical sites other than the lungs, the 
tracheobronchial tree, or the larynx [16].
Patients were excluded if they were diagnosed with and 
treated for latent TB infection or infection with the Bacillus 
Calmette-Guérin (BCG) strain of Mycobacterium bovis due 
to intravesical BCG instillation only. If TB was diagnosed 
and treatment completed outside of Denmark, cases were 
excluded.
Patients were followed from time of first contact with the hos-
pital due to EPTB until 1 year after TB treatment was completed.
Additional EPTB cases were included if a relapse/new epi-
sode of EPTB was identified in the patient record, and this case 
was not notified. A new episode/relapse was defined according 
to World Health Organization (WHO)/ECDC guidelines, and 
cases were only included once during a 12-month period [2, 
17].
Data Source
Notification Data
TB notification has been mandatory in Denmark since 1905 
and centralized since 1920 [18].
TB cases were diagnosed according to WHO definitions [17].
Microbiological Data
The International Reference Laboratory of Mycobacteriology 
at Statens Serum Institut performs mycobacteria diagnostics on 
all suspected TB cases in Denmark. This laboratory provided all 
bacteriological data.
Danish National Patient Registry
The Danish National Patient Registry (DNPR) contains data on 
all admissions to Danish public hospitals since 1977 and data on 
outpatient contacts since 1994 [19].
Data were obtained on all patients notified with TB in 
Denmark during the study period and on all patients who were 
assigned a TB diagnosis during the study period. Data from 
DNPR were used to calculate Charlson Comorbidity Index 
(CCI) scores [20] and to determine history of mental illness 
and previous TB diagnosis based on the patients' discharge 
diagnoses.
Data Linkage
To cross-link the registers, we used the unique Danish civil 
registration number (CRN), which is assigned to all residents 
of Denmark at birth or after residing legally in Denmark for 
3 months. Patients who do not meet the criteria for obtaining 
a CRN are assigned a temporary CRN at first point of contact 
with the health care system. To accommodate for alterations in 
temporary CRNs, probabilistic linkage was done.
Hospital Records
For all patients identified by the notification system, medical re-
cords were reviewed for sociodemographics, clinical character-
istics, and TB treatment. TB treatment outcome was obtained 
from hospital records, as reporting is voluntary and data 
from the Department of Infectious Disease Epidemiology & 
Prevention are incomplete [21]. TB treatment outcome was clas-
sified according to WHO definitions (Supplementary Table 1) 
[17].
Patient delay was calculated as time from TB-related 
symptom (constitutional symptoms: fever, weight loss, night 
sweats, and symptoms related to site of infection) onset until 
first hospital contact related to TB, whereas doctor delay was 
calculated as time from first TB-related contact with the health 
care system to start of TB treatment.
TB location was classified according to the origin of the 
sample submitted for culture and information from medical 
records. Cases that included >1 disease site were classified ac-
cording to their major site. TB location was further divided 
into superficial and deep disease; skin and/or peripheral lymph 
node TB was considered superficial disease.
Alcohol abuse was quantified according to the Danish Health 
Authorities' recommendations (>14 units per week of alcohol 
for women and >21 units for men) [22].
Nonadherence was defined as 2 or more instances of nonat-
tendance for clinical appointments and/or nonattendance de-
scribed in the patient record.
Immigrant status was defined as patients born abroad or 
those born in Denmark for whom 1 or both parents had been 
born abroad, including in Greenland.
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All hospital records were reviewed by I.K.H., and a preset 
format was used. In case of unclear interpretation, data were 
re-examined by a TB specialist: I.S.J.
Statistical Analysis
All EPTB cases were included in the data analysis describing pa-
tient characteristics. Categorical data were described by total 
numbers and percentages; the denominator for calculated 
percentages was the number of cases with known informa-
tion. Data comparisons were made using the chi-square test 
or Fisher exact test if 20% of the expected cell values were 
≤5. Continuous variables were described as medians and in-
terquartile ranges and compared using the Wilcoxon rank-
sum test. A  P value of <.05 (5%) was considered statistically 
significant.
In the data analysis describing predictors for unfavor-
able treatment outcome, multidrug-resistant (MDR; n  =  4), 
isoniazid-resistant EPTB treated with second-line drugs (n = 10) 
and patients who died (n = 15) or transferred out (n = 24) were 
excluded. Finally, 1 case was excluded due to missing medical 
record. Cases were excluded if the patient died or was trans-
ferred outside of Denmark during the observation period to 
ensure that all patients in the study population had a chance 
to complete treatment successfully. Treatment outcome was 
categorized into 2 groups: treatment completed or unfavorable 
outcome (the sum of treatment failed, treatment interrupted, 
and not evaluated). Characteristics of cases with unfavorable 
outcomes were compared with cases with treatment completion 
using univariable logistic regression. Variables for multivariable 
analysis were selected if they showed a univariable association 
with the unfavorable outcome (P < .05).
Incidence rates were calculated using the midyear estimates 
from Statistics Denmark [23]. The population was defined as 
contributing to 1 person-year per resident per year in the inci-
dence rate analyses. The crude annual incidence rates were cal-
culated as the number of incident cases per 100 000 person-years. 
Incidence rate ratios were assessed using Poisson regression.
Data from hospital records were entered into a Microsoft Excel 
2010 version 16.29.1 (Microsoft, Redmond, Washington, USA) 
workbook. All statistical analysis was performed using Stata, 
version 15.2 (StataCorp Inc., College Station, TX, USA).
Ethics
The study was approved by the Danish Data Protection 
Agency (Jnr. 15/34961) and the Danish Health Authority (Jnr 
3-3013-1213/1).
RESULTS
Population
Between January 1, 2009, and December 31, 2014, a total of 
2150 TB cases were notified, 36 cases were excluded (latent 
TB [n = 6], infection with BCG strain of Mycobacterium bovis 
due to intravesical BCG instillation [n = 4], double registration 
[n = 12], diagnosed and treated before 2009 or after 2015 [n = 6], 
misdiagnosed and TB treatment terminated [n = 7], diagnosed 
and treated outside of Denmark [n = 1]), and an additional 17 
cases were included due to relapse of TB that was not reported; 
this resulted in a total of 2131 cases. EPTB accounted for 450 
(21.1%) cases, who were all included in this study. The distri-
bution between PTB and EPTB did not change significantly 
from 2009 to 2014 (20.7%–20.8%), nor did the incidence rate of 
EPTB (1.23–1.17 per 100 000). When the study population was 
divided into immigrants (10.27–9.42 per 100 000) and Danes 
(0.28–0.14  per 100 000), there was still no significant change 
in incidence rates of EPTB during the study period (Figure 1).
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Figure 1. Extrapulmonary tuberculosis incidence rate in Denmark, 2009–2014.
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Sociodemographic and Clinical Characteristics
The general characteristics of the population are summarized 
in Table 1.
The population consisted of 373 (82.9%) immigrants and 77 
(17.1%) Danes (Table 1). Among immigrants, 353 (78.4%) were 
foreign born; of these, 99 (28.1%) patients were diagnosed with 
EPTB within 2 years of arrival. The majority of immigrants ori-
ginated from Asia (n  =  220; 59.0%); of these, Southeast Asia 
accounted for 44.1% (n = 97). Cases from Africa represented 
27.3% (n = 102), and 55.9% (n = 57) originated from Somalia. 
Europeans (n = 35; 9.4%) and Greenlanders (n = 16; 4.3%) com-
prised the remaining cases.
The median age of the study population (interquartile range 
[IQR]) was 35 (27–48) years. Danes were significantly older 
than immigrants (47 vs 33 years; P <  .01). Significantly more 
men were homeless, smokers, and had abused alcohol when 
compared with women (P < .01). The Danish cases were older 
and had higher CCI scores, and abuse of alcohol and tobacco 
was significantly more frequent among Danes when compared 
with immigrants (P < .01).
A total of 348 (75.3%) cases had an HIV test performed at any 
time during TB treatment. Nine tested positive for HIV. During 
the study period, the number of cases tested for HIV increased 
significantly, from 52.9% in 2009 to 95.5% in 2014.
The most common symptom at first contact was pain at 
the TB site and anemia. Patient delay was significantly longer 
among immigrants, whereas doctor delay was significantly 
longer among Danes (Table 1).
Site and Microbiological Characteristics of EPTB
The most common site of EPTB infection was lymph node 
(n = 246; 55.4%), followed by pleural TB (n = 62; 13.4%); this 
Table 1. Characteristics of Patients With Extrapulmonary Tuberculosis in Denmark, 2009–2014
Characteristics 
Danes Immigrants
n Na % n Na % P
Patients  77 17.1  373 82.9  
Sex        
 Male 46 77 59.7 183 373 49.1 .09
Age, y        
 Median (IQR) 47 77 (32–62) 33 373 (26–44) <.01
 0–24 12 77 15.6 70 373 18.8 <.01
 25–44 26 77 33.8 210 373 56.3  
 45–64 22 77 28.5 82 373 22.0  
 ≥65 17 77 22.1 11 373 2.9  
Predisposing factors        
 Alcohol 17 76 22.4 16 341 4.7 <.01
 Tobacco 34 76 44.7 84 336 25.0 <.01
 Cannabis 4 75 5.3 9 2.7 337 .23
 History of illegal drug use 3 77 3.9 7 368 1.9 .28
 Homelessness 2 77 2.6 9 371 2.4 .93
 History of incarceration 0 77 0 3 368 0.8 .43
 Previous TB 8 69 10.4 31 357 8.7 .64
Charlson comorbidity score        <.01
 0 37 77 48.0 288 356 80.9  
 1 18 77 23.4 39 356 11.0  
 ≥2 22 77 28.6 29 356 8.1  
Identification by contact tracing 9 77 11.7 6 368 1.6 <.01
Delay        
 Patient delay, median (IQR), d 30 61 (9–120) 60 336 (26–120) <.01
 Doctors' delay, median (IQR), d 38.5 70 (14–82) 28 358 (12–63) <.01
 Total delay, median (IQR), d 90 58 (53–180) 98 328 (46–184) <.01
Symptoms at first contact        
 Weight loss 27 76 35.5 139 365 38.1 .68
 Night sweat 23 72 31.9 115 349 33.0 .87
 Fever 24 76 31.6 141 366 38.5 .26
 Pain TB site 25 76 32.9 164 367 44.7 .06
 Anemiab 23 40 57.5 72 167 43.1 .10
Abbreviations: IQR, interquartile range; TB, tuberculosis.
aInformation was not available on all included patients.
bWomen: Hgb < 7.5 mmol/L. Men: Hgb < 8.0 mmol/L.
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was applicable among all age groups and across immigration 
status (Table 2). There was a significant disparity in the distri-
bution of EPTB within age groups. TB meningitis was most fre-
quent among the 0–24-year age group (odds ratio [OR], 6.27; 
P < .05), whereas lymph node TB was more common in the age 
group 24–44 years (OR, 2.55; P < .05). Pleural TB was most fre-
quent among those age 45–64 years (OR, 1.96; P < .05). Finally, 
urogenital TB was most common in the age group >64  years 
(OR, 4.39; P = .05).
Only 18 (3.5%) cases had a concomitant site of infection 
and fulfilled the criteria for disseminated TB; 1 of these was 
co-infected with HIV, and all cases were immigrants.
In total, 55 (12.2%) patients with EPTB were previously 
treated. Among these, 5 patients relapsed within 12  months. 
Two patients were diagnosed and initiated TB treatment out-
side of Denmark. In 406 cases, a clinical specimen was sampled 
for microbiologic diagnostics: 90 (20.1%) cases were smear 
positive, 328 (73.2%) cases were Mycobacterium tuberculosis 
culture positive, and 87 (26.6%) cases were smear and culture 
positive. In 291 (88.7%) cases, drug susceptibility testing was 
done (Table 2). Isoniazid monoresistance was identified in 
22 (4.9%) cases, MDR-TB in 4 (0.9%) cases, and none of the 
cases had XDR-TB (Table 2). A nucleic amplification test was 
performed in 352 cases, of which 214 (60.6%) were positive. 
A total of 103 (22.9%) cases were diagnosed on clinical criteria 
only.
Treatment
A total of 444 cases started TB treatment. The remaining 6 pa-
tients (1.3%) died before treatment was initiated. The median 
treatment duration (IQR) was 6 (6–7) months. Among the 
drug-susceptible EPTB cases, 216 (51.1%) received the standard 
treatment of 2 (3 months) (the national guideline was modified 
in 2010; the intensive phase was decreased from 3 to 2 months) 
months of intensive-phase treatment including 4 drugs (rifam-
picin, isoniazid, pyrazinamide, ethambutol) and 4  months of 
Table 2. Disease Site and Microbiological Characteristics of Patients With Extrapulmonary Tuberculosis in Denmark, 2009–2014
Characteristics 
Danes Immigrants 
n Na % n Na % P
Site of disease       <.01
 Pleural 23 77 29.9 39 373 10.5  
 Lymphatic 30 77 39.0 216 373 57.9  
 Spondylodiscitis 2 77 2.6 32 373 8.6  
 Abdominal 3 77 3.9 25 373 6.7  
 Genitourinary 3 77 3.9 12 373 3.2  
 Meningitis 3 77 3.9 12 373 3.2  
 Skin 4 77 5.2 8 373 2.4  
 Bone and joint 3 77 3.9 10 373 2.7  
 Intracerebral 0 77 0 2 373 0.5  
 Ocular 4 77 5.2 9 373 2.4  
 Otherb 0 77 0 5 373 1.3  
Superficial diseasec 34 77 44.2 220 373 59.0 .02
Deep tissue disease 43 77 55.8 153 373 41.0  
Concomitant site        
 Any 0 77 0 18 373 4.8 .05
 >1 0 77 0 1 373 0.3 .65
Diagnosed supported by        
 Culture positive 46 66 69.7 282 341 82.7 .02
 Smear positive 11 66 16.7 79 340 23.2 .24
Nucleic amplification        
 Positive 33 53 62.3 181 299 60.5 .81
 Tuberculin skin test 7 9 77.8 19 23 82.6 .75
 IGRA 30 44 68.2 180 216 83.3 <.01
Drug resistance        
 INH mono-resistance 1 37 2.7 21 254 8.3 .23
 MDR (INH and RIF resistance) 0 37 0 4 254 1.6 .44
 XDR TB 0 37 0 0 254 0 0
Abbreviations: IGRA, interferon gamma release assay; INH, isoniazid; MDR, multidrug-resistant; RIF, rifampicin; TB, tuberculosis; XDR, extensively drug-resistant TB resistant to isoniazid and 
rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs.
aInformation was not available on all included patients.
bGenitourinary tract, cerebral other than meningitis, pericarditis, abscess.
cSuperficial site of disease: lymph node or/and skin.
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continuation-phase treatment including 2 drugs (rifampicin, 
isoniazid).
TB Treatment Outcome
Treatment completion increased from 79.4% to 90.9% during 
the study period (Figure 2).
The highest risk for unfavorable treatment outcome was in 
the age group 0–24 years, and all patients were between 15 and 
24  years old. Among these, the majority were male (66.7%), 
and 88.9% were immigrants. None of these patients smoked 
or abused cannabis, alcohol, or narcotics or were homeless. All 
were lost to follow-up and did not complete TB treatment. The 
median time of treatment (IQR) was 2 (1.6–3.5) months. One 
of the patients returned to the hospital 1.5 years later with pul-
monary TB and completed TB treatment.
In total, 15 patients died. These patients were significantly 
older (mean age, 58 vs 37  years) and had higher CCI scores 
(median CCI, 0 vs 3) when compared with the remaining cases. 
Of those who died, Danes represented 60% of the patients. Nine 
patients initiated treatment. The median treatment duration 
(IQR) was 1.1 (1–3.5) months. The majority of the patients who 
died had pleural TB (40%). Two patients were diagnosed with 
TB meningitis, and another 2 patients had lymphatic TB. None 
of the patients had a concomitant site of infection.
Table 3 shows the final multivariable model fitted on 395 
cases. A significantly increased risk of an unfavorable outcome 
was found among males and among patients <25 years of age.
DISCUSSION
In this nationwide study, we found that EPTB mainly affects 
young healthy immigrants from high-incidence countries. 
Lymph node TB was the most frequent site of EPTB. In spite 
of significant patient delay, the overall treatment completion 
rate was high and increased during the study period (P = .06). 
Unfavorable outcome was significantly associated with male 
gender and age 0–24 years.
In Denmark, the incidence of TB increased marginally from 
2009 to 2012 (6.0–6.9 per 100 000) and declined thereafter [24]. 
The increase in TB was caused by an increased incidence in TB 
among immigrants [25]. The overall incidence of EPTB peaked 
in 2013 and decreased thereafter; however, this was not signifi-
cant. The proportion of EPTB followed the same trend. Hence, 
we did not find a significant change in incidence or proportion 
of EPTB in Denmark during our study period. The proportion 
of PTB was persistently high, and the smear positivity among 
PTB cases was high at 54.6% during the study period, which is a 
predictor for insufficient TB control in Denmark [21].
The localization of EPTB has been related to age, gender, and 
ethnicity. We found that lymph node TB was the most common 
site of EPTB, followed by pleural TB. In addition, certain types 
of EPTB were associated with specific age groups. This is in line 
with earlier studies from low-incidence countries [7, 15, 26–31]. 
Earlier studies from high-incidence countries have indicated 
that EPTB is associated with female sex [32, 33]. We were not 
able to demonstrate this, as 50.9% were males. However, this is 
in accordance with studies from other low-incidence countries 
[8, 34, 35].
Overall, TB treatment completion rates were high and did 
increase during the study period, reaching 90.9% in 2014. 
We recently found an overall treatment completion rate of 
86.6% in 2014 in pulmonary TB [21]. This difference could 
be explained by higher adherence and less substance abuse 
2014
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Figure 2. Extrapulmonary tuberculosis treatment outcome in Denmark, 2009–2014.a aNone of the patients had the following outcome: treatment failed, not evaluated, or 
still on treatment.
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and homelessness in the EPTB group. A Finnish study found 
a treatment completion rate of 56.9% in patients with EPTB; 
however, these patients were older (median age, 70.1 years) 
and had more comorbidities, and immigrants only repre-
sented 10.9% [8]. A  study from Texas reported an EPTB 
treatment completion rate of 82.5%. The study population 
differed in terms of higher prevalence of HIV and drug use. 
Location of EPTB close to the central nervous system and 
peritoneum was more frequent [5]. This emphasizes that 
even between low-incidence countries, TB treatment out-
comes can be challenging to compare without knowledge re-
garding risk factors and comorbidity.
Table 3. Odds Ratio for Unfavorable Outcome vs Treatment Completion Among EPTB Patients in Denmark, 2009–2014
Characteristics at Time of EPTB Diagnosis
No. of Cases (%)
Factors Associated With 
Unfavorable Treatment 
Outcome, Univariate 
Logistic Regression
Factors Associated 
With Unfavorable 
Treatment Outcome, 
Multivariate Logistic 
Regression
Unfavorable Outcome Treatment Completion OR 95% CI OR 95% CI
Total 20 (5.1) 376 (94.9)     
Sex       
 Female 4 (2.0) 195 (98.0) RF    
 Male 16 (8.2) 181 (91.8) 4.33 1.42–13.23 5.18 1.79–15.04
Age, y       
 0–24 9 (12.3) 64 (87.7) 13.36 1.65–108.32 16.39 2.02–132.64
 25–44 9 (4.4) 195 (95.6) 4.41 0.55–35.39 4.44 0.55–35.64
 45–64 1 (1.0) 95 (99.0) RF  RF  
 ≥65 1 (4.4) 22 (95.6) 4.32 0.26–72.01 5.73 0.33–100.3
Country of origin       
 Denmark 3 (4.5) 64 (95.5) RF    
 Other 17 (5.2) 313 (94.8) 1.17 0.33–4.11   
Predisposing factors       
 Alcohol 2 (7.4) 25 (92.6) 1.87 0.40–8.73   
 Tobacco 7 (6.7) 98 (93.3) 1.98 0.72–5.49   
 Cannabis 2 (16.7) 10 (83.3) 4.83 0.96–24.4   
 History of illegal drug use 1 (12.5) 7 (87.5) 2.75 0.32–23.58   
 Homelessness 2 (20.0) 8 (80.0) 5.08 1.00–25.74   
 History of incarceration 0 (0.0) 1 (100.0) NA    
 Previously TB 3 (8.6) 32 (91.4) 2.09 0.57–7.70   
 History of mental illness 2 (11.8) 15 (88.2) 2.67 0.57–12.58   
Charlson comorbidity score       
 0 17 (5.8) 275 (94.2)     
 1 0 (0.0) 52 (100.0)     
 ≥2 1 (2.4) 40 (97.6) 0.05–3.12 0.38   
Concomitant site       
 Any 0 (0.0) 14 (100.0) NA    
 Superficial site of diseasec 11 (4.8) 218 (95.2) RF    
 Deep site of disease 9 (5.4) 158 (94.6) 1.12 0.45–2.78   
Diagnosis supported by:       
 Culture positive 16 (5.0) 307 (95.0) 0.90 0.29–2.79   
 Identification by contact tracing 0 (0.0) 13 (100.0) NA    
Clinical symptoms       
 Symptom duration >30 d 11 (5.1) 205 (94.9) 1.18 0.42–3.27   
 Time to diagnosis >30 d 8 (4.2) 181 (95.8) 0.81 0.31–2.10   
 Weight loss 8 (5.6) 136 (94.4) 1.14 0.45–2.87   
 Fever 10 (7.1) 131 (92.9) 1.85 0.75–4.56   
 Night sweet 9 (7.3) 114 (92.3) 1.70 0.68–4.23   
 Adherenceb 3 (0.8) 357 (99.2)     
 Nonadherence 16 (48.5) 17 (51.5) 112 29.7–422.38   
Abbreviations: CI, confidence interval; EPTB, extrapulmonary tuberculosis; OR, odds ratio; RF, reference; TB, tuberculosis.
aA total of 395 cases were included in the multivariable analysis.
bNonadherence: if described in patient records and/or ≥2 episodes of nonattendance for clinical appointments.
cSuperficial site of disease: lymph node or/and skin.
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All patients classified as having an unfavorable outcome were 
lost to follow-up. In line with an earlier study, men were identi-
fied to be at significantly higher risk for unfavorable treatment 
outcomes [8]. This could be partly explained by a significantly 
higher frequency of use of cannabis, alcohol abuse, and being 
homeless, all factors that contribute to poor adherence among 
men with EPTB. The risk of an unfavorable outcome was sig-
nificantly associated with the age group 0–24  years. All these 
patients were lost to follow-up. We did not find any known risk 
factors for being lost to follow-up: for example, abuse of alcohol 
or drugs or homelessness. However, these patients were pre-
dominantly immigrants and might have experienced language 
difficulties that led to misunderstandings regarding treatment 
and follow-up.
Treatment outcome was evaluated at the time of treatment 
completion and categorized as successful if there were no signs 
of failure according to the current definition by the WHO [17]. 
Signs of failure were typically assessed by clinical appearance, 
advanced imaging techniques, inflammation markers, and Hgb. 
New tissue samples were often not collected, as this would in-
volve an invasive procedure; consequently, these patients could 
not be classified as having experienced treatment failure. In line 
with earlier studies, we suggest that treatment outcomes should 
be assessed 12 months after treatment completion, and in case 
of relapse, the treatment outcome should be categorized as 
treatment failure [36, 37].
Immigrants had a significantly longer patient delay than 
Danes. The Danish health care system provides free and equal 
health care to all legal residents in Denmark; hence the patient 
delay among immigrants cannot be explained by inequality in 
access to health care. However, immigrants might experience 
language barriers that result in misunderstandings and misin-
terpretations when approaching the health care system. This 
emphasizes the need for professional translators. In addition, 
cultural differences can cause delay in seeking professional 
care, as TB still is stigmatizing in many high-incidence coun-
tries [38, 39]. Doctor delay was significantly higher among 
Danes when compared with immigrants. This might be ex-
plained by less suspicion of EPTB among Danes because of a 
low incidence of EPTB in this group. The fact that Danes were 
older and had coexisting illness could have made the EPTB di-
agnosis difficult and contributed to delay. In a recent study, we 
found that doctor delay in pulmonary TB was much lower for 
both Danes and immigrants (9 and 5 days, respectively) [21]. 
EPTB can be challenging to diagnose, as the disease can affect 
virtually all organs and the clinical presentation can be non-
specific. As a result, these patients can present to doctors with 
minimal experience with TB. In addition, the EPTB site can be 
relatively inaccessible, causing sampling of a specimen to be 
challenging.
This is the first study to provide a complete review of EPTB treat-
ment outcomes during a 6-year period in Denmark. Additionally, 
this study provides clinical data as well as comprehensive outcome 
information on a large group of Danish EPTB patients. However, 
the study has limitations: The population was identified by noti-
fication data; hence patients who were not notified were not in-
cluded. This could have introduced selection bias. Yet, a recent 
study from Denmark has assessed the underreporting of TB to 
7.5% in the same period. The non-notified cases were all culture-
negative and did not differ significantly in treatment outcomes 
and risk factors from the notified cases [40]. All clinical informa-
tion was from hospital records; hence there was no direct patient 
contact. The quantity and quality of information solely depended 
on the hospital records. Treatment was prolonged in patients who 
did not respond satisfactorily, and new samples were not collected 
because of the risk associated with an invasive procedure. This has 
potentially led to an underestimation of treatment failure. Patients 
who were lost to follow-up may still have completed treatment. 
However, this concern is limited, as the CRN allowed us to trace 
patients who appeared at another hospital or emigrated during the 
study period. CCI could not be assessed for patients with tempo-
rary CRNs, because they were not registered in the DNPR. These 
patients accounted for 3.8% (n  =  17) of the entire population. 
Finally, the number of patients with an unfavorable outcome was 
relatively small, thereby decreasing the power of the study and po-
tentially preventing us from identifying predictors associated with 
an unfavorable outcome.
CONCLUSIONS
EPTB represents a significant number of TB cases in Denmark. 
Doctor delay was significantly longer among Danish patients, 
which emphasizes that EPTB should be considered a differ-
ential diagnosis in Danish patients, especially in the older age 
group. Even with a treatment completion rate as high as 90.9% 
in 2014, a continuous effort is needed to prevent unfavorable 
outcomes and mortality, especially among males and those aged 
<25 years, which as male sex and age <25 years were identified 
as risk factors for an unfavorable outcome.
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